We have located links that may give you full text access.
P235Viral-delivered gene therapy for treatment of CPVT.
Cardiovascular Research 2014 July 16
Catecholaminergic polymorphic ventriculartachycardia (CPVT) is a lethal human arrhythmia provoked by exercise or emotional stress. It is mediated by abnormal calcium release from the sarcoplasmic reticulum through "leaky" ryanodine channels. Beta-adrenergic blockers are the therapy of choice for human CPVT but they fail to achieve complete arrhythmia control in some of the cases. Gene therapy is a potential treatment for genetic and other diseases associated with inadequate expression of a key protein.We established a new gene-delivery system to target CASQ2 knock-out mice suffering from CPVT2. CASQ2 gene was cloned into pAAV-IRES-hrGFP plasmid. AAV9 recombinant vectors were generated by co-transfecting the expression plasmid into the AAV-293 cells with pHelper (carrying adenovirus-derived genes) and pAAV-RC (carrying AAV-9 replication and capsid genes), which express the transacting factors required for AAV replication and packaging in the AAV-293 cells. Viral particles were purified from crude cell lysates, concentrated and injected into the left ventricle of 12-14-week-old mice. Mice underwent provocation testing for arrhythima 7 weeks post viral infection. Cryosections staining demonstrated that cardiac muscle and lung tissues were CASQ2 and GFP positive while liver and spleen were GFP negative in the infected mice. Calsequestrin protein expression was elevated in the hearts of infected CASQ2 knock-out mice (n=10) compared to controls. A dose-dependent reduction in abnormal ventricular beats was observed in mice that expressed AAV9-delivered myocardial CASQ2 protein (R2=0.723, p<0.005).Viral gene-delivery eliminated sustained ventricular tachycardia in all infected mice (p=0.012) while more than 33% of the normal protein level was required to prevent non-sustained VT (n=5, p=0.003). In conclusion, we assembled a vector useful for cardiac gene delivery, thus creating a platform for gene therapy studies in inherited heart diseases. In vivo viral delivery of CASQ2 cDNA attenuated ventricular arrythmia in mice with CPVT2.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app